Purpose: The aim of this study was to determine the effect of posterior vitreous detachment on outcome of anti–vascular endothelial growth factor injection.
Methods: Sixty-one eyes with age-related macular degeneration that had received intravitreal bevacizumab or ranibizumab injections were retrospectively reviewed. The vitreomacular interface was evaluated, and eyes were grouped according to the presence of posterior vitreous detachment (Group 1, n = 25) or vitreomacular adhesion (Group 2, n = 36). All patients received three loading doses of intravitreal anti–vascular endothelial growth factor injections at monthly intervals, and subsequently, pro re nata regimen was performed. Best-corrected visual acuity and central foveal thickness measurement at follow-up were evaluated. The development of posterior vitreous detachment during the follow-up was also reported.
Results: The best-corrected visual acuity changes at each visit compared with baseline were significantly better in Group 1 (P = 0.01, 0.02, 0.02, 0.009, 0.009, respectively at third, sixth, ninth, 12th month, and last visit). When best-corrected visual acuity was classified according to the change in visual acuity of 10 letters or more, the rate of improved or stable best-corrected visual acuity was greater in Group 1 (P = 0.02). During the follow-up, 5 eyes (14.3%) developed posterior vitreous detachment.
Conclusion: Vitreomacular adhesion seems to have an adverse effect on the visual prognosis of anti–vascular endothelial growth factor treatment for age-related macular degeneration.
Eyes with vitreomacular adhesion (n = 25) at baseline seems to have worse prognosis than those without vitreomacular adhesion (n = 36) after intravitreal anti&#x2013;vascular endothelial growth factor injection treatment.
Ministry of Health Ankara Training and Research Hospital, Ophthalmology Clinic, Altindag, Ankara, Turkey.
Reprint requests: Güner Ö. Üney, MD, SB Ankara Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, Altindag, Ankara, TR06520, Turkey; e-mail: email@example.com
None of the authors have any financial/conflicting interests to disclose.